Currently, the most effective treatment for brain ischemic stroke is recombinant tissue plasminogen activator (rt-PA); however, increased incidence of symptomatic intracerebral hemorrhage severely reduced its favorable treatment outcome.
We aimed to investigate the effect of ginsenoside (Gs) on symptomatic intracerebral hemorrhage after rt-PA treatment. Stroke patients were randomly divided into 2 treatment groups, one receiving rt-PA + placebo (Pc) and the other rt-PA + Gs. Twenty-four hours after the treatment, outcomes were assessed with transcranial Doppler (TCD) ultrasonography and National Institutes of Health Stroke Scale (NIHSS), and plasma levels of transforming growth factor-β1 (TGF-β1), matrix metalloproteinase (MMP)-2, and MMP-9 were also measured. After initial cotreatment, the patients were continuously administered with either Pc or Gs, and the treatment outcomes at 7 days were assessed with TCD, NIHSS, modified Rankin scale (MRS), and Glasgow outcome scale (GOS).
Cotreatment of rt-PA with Gs significantly improved outcomes in patients compared to the Pc group, as indicated by improved TCD and NIHSS scores and reduced incidence of symptomatic intracerebral hemorrhage, which could be attributed to a Gs-induced increase in TGF-β1 and a decrease in both MMP-2 and MMP-9 serum levels. Seven days of Gs treatment also significantly improved outcomes in patients compared to the Pc group, assessed by TCD, NIHSS, MRS, and GOS.
Our study supports the clinical use of Gs as a potential supplement with rt-PA treatment, which reduces symptomatic intracerebral hemorrhage, therefore improving the treatment outcome of stroke patients.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Stroke and Cerebrovascular Diseases
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010.Lancet. 2014; 383: 245-254
- Tissue plasminogen activator for acute ischemic stroke.N Engl J Med. 1995; 333: 1581-1587
- Improving reperfusion therapy for acute ischaemic stroke.J Thromb Haemost. 2011; 9: 333-343
- Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke.Stroke. 2004; 35: 2726-2730
- Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).J Clin Pharm Ther. 2012; 37: 620-629
- Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia.Neurosurg Focus. 2007; 22: E4
- Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies.CNS Neurol Disord Drug Targets. 2008; 7: 243-253
- Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain.J Cereb Blood Flow Metab. 2009; 29: 715-725
- Thrombolysis with alteplase for acute ischemic stroke patients with atrial fibrillation.Neurol Res. 2010; 32: 353-358
- Transforming growth factor beta1 signalling, wound healing and repair: a multifunctional cytokine with clinical implications for wound repair, a delicate balance.Postgrad Med J. 2009; 85: 9-14
- Transforming growth factor-beta suppresses tumor necrosis factor alpha-induced matrix metalloproteinase-9 expression in monocytes.J Leukoc Biol. 2001; 69: 613-621
- Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-beta is mediated by a nuclear factor-kappaB site.Biochem J. 2004; 381: 413-422
- Transforming growth factor-beta signaling alters substrate permeability and tight junction protein expression at the blood-brain barrier during inflammatory pain.J Cereb Blood Flow Metab. 2009; 29: 1084-1098
- TGF-beta1 prevents blood-brain barrier damage and hemorrhagic transformation after thrombolysis in rats.Exp Neurol. 2015; 266: 120-126
- Ginsenosides chemistry, biosynthesis, analysis, and potential health effects.Adv Food Nutr Res. 2009; 55: 1-99
- Suppression of local inflammation contributes to the neuroprotective effect of ginsenoside Rb1 in rats with cerebral ischemia.Neuroscience. 2012; 202: 342-351
- [Effects of ginsenoside and berberine on secretion of immunosuppressive cytokines in lung carcinoma cell line PG].Zhong Xi Yi Jie He Xue Bao. 2008; 6: 278-282
- Pilot study of new diagnostic criteria for middle cerebral artery stenosis by transcranial Doppler.J Neuroimaging. 2010; 20: 122-129
- Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group.Stroke. 1994; 25: 2220-2226
- Interobserver agreement for the assessment of handicap in stroke patients.Stroke. 1988; 19: 604-607
- Observer variability in assessing impaired consciousness and coma.J Neurol Neurosurg Psychiatry. 1978; 41: 603-610
- Thrombectomy within 8 hours after symptom onset in ischemic stroke.N Engl J Med. 2015; 372: 2296-2306
- Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction.J Cereb Blood Flow Metab. 1999; 19: 1020-1028
- Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia.Am J Physiol Heart Circ Physiol. 2005; 289: H558-H568
- Combination therapy of 17beta-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke.J Pharmacol Exp Ther. 2010; 332: 1006-1012
- Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke.Circulation. 2003; 107: 598-603
- Metalloproteinase and stroke infarct size: role for anti-inflammatory treatment?.Ann N Y Acad Sci. 2010; 1207: 123-133
Published online: December 09, 2015
Accepted: November 3, 2015
Received in revised form: October 19, 2015
Received: September 2, 2015
Grant support: This work was supported by the Youth Excellent Talents Training Program of Pudong Health Bureau of Shanghai (Grant No. PWRq2013-06).
© 2016 National Stroke Association. Published by Elsevier Inc. All rights reserved.